- Considerations for live-biotherapeutic development and applicability: reviewing microbiota variation, biomarkers, and metabolites.
- Integrating a personalization approach to therapeutic discovery, linking clinical trial outcomes with in-vitro results obtained from the PMAS system.
- How to harness the metabolome to guide the next generation of live-biotherapeutics.
Yosep Ji, Chief Executive Officer, HEM Pharma
Speaker(s):
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/yosep_ji.jpg?itok=WHQcEL4o&c=38cad801bf8b6582aeb803925b0aa800)
Yosep Ji
Chief Executive Officer
HEM Pharma